Hy-Vee brings telepharmacy locations to 2 Iowa communities
WEST DES MOINES, Iowa — Two rural communities in Iowa will now have Hy-Vee pharmacy services. The retailer purchased two telepharmacies — one in Victor and another in Liberty — that will continue to operate under its name. The locations opened Nov. 6.
Hy-Vee said its telepharmacies offer patients a direct line to pharmacists and can process prescriptions similarly to how a retail pharmacy would do so. The telepharmacies are staffed with certified pharmacy technicians and pharmacists can counsel patients via iPad and telephone, the company said, adding that pharmacists can double check the accuracy of a fill using digital equipment.
“We are thrilled to provide Hy-Vee pharmacy services and maintain a personal pharmacist connection for residents in Victor and West Liberty, Iowa, through our new telepharmacy locations,” Hy-Vee senior vice president and chief health officer Kristin Williams said. “Enhancing health care for our customers is a top priority, and these locations will fill prescriptions as well as offer additional health and wellness services that Hy-Vee is known for.”
The locations also offer OTC and convenience products for purchase. A pharmacist will be on-store 16 hours monthly.
Dr. Reddy’s introduces generic Clolar injection
PRINCETON, N.J. — Dr. Reddy’s Laboratories has launched its generic of Genzyme’s Clolar (clofarabine, 1 mg/ml) injection. The drug is indicated as a treatment for patients ages 1 to 21 years with relapsed or refractory lymphoblastic leukemia after two prior regimens.
The product had brand and generic sales of roughly $53 million for the 12 months ended September 2017, according to IQVIA data. The drug will be available in single-dose 20-ml vials.
Upsher-Smith parent Sawai inks deal with Sumitomo
Upsher-Smith parent Sawai
MAPLE GROVE, Minn. — Sawai Pharmaceuticals, the parent company of Upsher-Smith Laboratories, has announced a new strategic alliance with Japanese trading house Sumitomo. The alliance will see Sawai sell a 20% stake in its American subsidiary to Sumitomo’s U.S. arm for $211 million.
“Sumitomo's investment in our U.S. subsidiary and its management participation in Upsher-Smith will allow us to benefit from its experience, knowledge and network in the global business arena in areas such as sourcing of active pharmaceutical ingredients and product introduction,” Sawai president Mitsuo Sawai said. “By leveraging the unique strengths of the three companies, namely Sawai, Upsher-Smith and Sumitomo Corporation, we will continue to enhance our global presence, including the U.S. business, to accelerate growth with the goal of becoming ‘a globally recognized generics company.’”
Upsher-Smith said Sumitomo is known for its abilities to expedite ideas and distribute products through a global network of offices. Core business units of Sumitomo include tubular products, environment and infrastructure, steel and non-ferrous metals, transportation and construction systems and several others.
“We are excited by the potential of this partnership and look forward to increasing our capacity for acquisition and discovering broader strategic growth opportunities,” Upsher-Smith president and CEO Rusty Field said.
The sale is expected to close by the end of March 2018.